In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

PCSK-9 inhibitors, like evolocumab (Rapatha), were shown in one study to have no increased risk of muscle damage, despite case reports of the disease worsening. Bempedoic acid (Nexlotol ...

PCSK-9 inhibitors, like evolocumab (Rapatha), were shown in one study to have no increased risk of muscle damage, despite case reports of the disease worsening. Bempedoic acid (Nexlotol ...

These products included Repatha (evolocumab), Tezspire (tezepelumab-ekko), Evenity (romosozumab-aqqg), Tavneos (avacopan), and Blincyto (blinatumomab). A 17% growth was seen across Amgen’s innovative ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...